I am very skeptical of Cymbalta. Lilly hid negative events from their drug trials with it, including a person who committed suicide on Lilly property who was in the "normal" group using it. It was a young woman in college.
http://www.yourlawyer.com/topics/overview/cymbalta

Cymbalta does not improve neuropathy. It just changes your perception of it.
It is basically like Effexor, it is a me-too drug. Only Lilly was clever and did some
studies with diabetics and got approval for it for diabetic neuropathy...so it would look like a competitive edge to doctors, who of course jumped at it. All SSRI/SSNI's have been used for pain relief, and Cymbalta is not special in that regard, chemically.

All of the drugs that work on depression, mood, psychiatric issues, all affect certain neurotransmitters. What researchers learned many years after these were approved (often with only weeks of data behind them) is that the brain accommodates to the drug and shifts the ratios of neurotransmitters around.
For example SSRI's downregulate dopamine.

Your Wellbutrin works primarily on the dopamine system, and the Cymbalta
on serotonin and norepinephrine. So those two drugs are affecting 3 systems for you. And at this time we don't know what exactly happens then.

Your decision to increase doses is yours. But I remain skeptical...since we really only have learned a little bit about what is really going on inside.

Also use of a triptan drug like Relpax with SSRI drugs should be done carefully, at this time because data is confusing about it:
http://www.nelm.nhs.uk/Record%20View...aspx?id=547347

http://www.clinicalanswers.nhs.uk/in...?question=1947
Venafaxine is very similar chemically to Cymbalta.

Cymbalta remains the only SSRI that causes liver damage. This should be tested for, and raising doses, increases that risk.
Also SSRI drugs have recently been implicated in osteoporosis ...new studies show causation for them in reducing bone density.
http://findarticles.com/p/articles/m...1/ai_n13471771